Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases

E-ISSN： 1873-5592|18|10|1214-1224

ISSN： 1389-4501

Source： Current Drug Targets, Vol.18, Iss.10, 2017-07, pp. : 1214-1224

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

14-3-3 zeta as novel molecular target for cancer therapy

By Matta Ajay Siu KW Michael Ralhan Ranju

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 5, 2012-05 ,pp. : 515-523

Informa Healthcare

Access to resources Recommend Favorite

CCN2: a novel, specific and valid target for anti-fibrotic drug intervention

By Leask Andrew

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 9, 2013-09 ,pp. : 1067-1071

Informa Healthcare

Access to resources Recommend Favorite

Chromatin Organizer SATB1 As a Novel Molecular Target for Cancer Therapy

Current Drug Targets, Vol. 13, Iss. 13, 2012-12 ,pp. : 1603-1615

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases

Current Medicinal Chemistry, Vol. 22, Iss. 33, 2015-11 ,pp. : 3765-24

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Novel Selective Pharmacophore for Tankyrase Inhibitors

Letters in Drug Design & Discovery, Vol. 14, Iss. 10, 2017-09 ,pp. : 1164-1175

Bentham Science Publishers

Access to resources Recommend Favorite